ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA agrees to review Pfizer’s NDAs for tafamidis
January 16, 2019The US Food and Drug Administration (FDA) has accepted Pfizer’s two new drug applications (NDAs) for tafamidis to treat transthyretin amyloid cardiomyopathy (ATTR-CM)..... -
Pfizer’s tafamidis reduces risk of death by 30 %, reveals study
August 29, 2018Pfizer has anounced that the recent study has revealed, tafamidis drug reduced the risk of death for patients with a rare and fatal heart disease by around 30 per cent, boosting the prospects of what could be a billion-dollar-a-year drug.
Pharma Sources Insight January 2025
